Tarsus Pharmaceuticals’ shares jumped after a regulatory milestone in China tied to its partner's drug approval. The company said it will receive a $15 million milestone payment following Grand Pharmaceutical Group’s approval of TP-03 for the treatment of Demodex blepharitis in China. On Monday, Tarsus stock rose 3.5% to $62.25.
TP-03, marketed as Xdemvy in the United States, won approval to treat Demodex blepharitis - an eyelid disorder caused by microscopic mites that produces itching and irritation. Tarsus described the product as the first approved therapy for this condition in China.
Under the commercial arrangement, Grand Pharmaceutical Group holds exclusive rights to develop and sell TP-03 across Greater China, specifically including mainland China, Hong Kong, Macau and Taiwan. The company noted that more than 40 million people in the region are affected by the condition.
Tarsus also confirmed it remains eligible to receive additional payments tied to future regulatory and sales milestones, as well as ongoing royalties from product sales. Those contingent payments are separate from the immediate $15 million milestone now due following the approval.
Context and market implications
The announced milestone payment and the stock response reflect the immediate financial effect of a partner securing a major regulatory nod in a large regional market. The exclusive Greater China license held by Grand Pharmaceutical Group makes that partner responsible for further development and commercialization activities in the territory where Tarsus does not hold direct marketing rights.
What the company reported
- Tarsus will receive a $15 million milestone payment tied to the China approval for TP-03.
- TP-03 is approved in China to treat Demodex blepharitis and is marketed as Xdemvy in the U.S.
- Grand Pharmaceutical Group controls exclusive development and sales rights in Greater China.
- Tarsus is eligible for additional regulatory and sales milestones and future royalties.
Note: The information above reflects the company announcement regarding the China approval, the executed commercial rights for Greater China, the milestone payment amount, and the reported regional patient estimate. It does not include projections or additional claims beyond those provided in the company statement.